In the field of chronic pain management, radiofrequency thermocoagulation is a well-established and effective minimally invasive interventional technique. The performance of its core device-the radiofrequency thermocoagulation electrode cannula needle (commonly referred to as the RF puncture needle)-directly affects the precision and safety of treatment. Beijing Beiqi Medical Technology Co., Ltd., along with its agency for the German brand Inomed, offers an original imported "radiofrequency thermocoagulation electrode cannula needle" that holds significant influence in this niche market. Its development journey reflects the evolution of China's pain intervention devices from technology importation to independent innovation.

1. Manufacturer and Product Background: A Model of Sino-Foreign Collaboration

Beijing Beiqi Medical, established in 2005, is a national high-tech enterprise that has long focused on the research, development, production, and sales of minimally invasive treatment devices for pain management, orthopedics, rehabilitation, and neurosurgery. Its core product line includes the R-2000B series radiofrequency temperature-controlled coagulators, along with disposable radiofrequency electrodes, introducer needles, and other accessories. Beiqi Medical is not only a device manufacturer but also the sole distributor in China for consumables such as radiofrequency introducer needles from Germany's Innomend Company, offering a complete "equipment + consumables" solution.

Inomed, a German medical technology company, is a globally recognized supplier of devices in neurosurgery and pain intervention, renowned for its radiofrequency thermocoagulation electrode cannula needles, which are distinguished by superior craftsmanship and reliable quality. By combining internationally leading consumables with self-manufactured equipment, Beiqi Medical offers Chinese pain clinics high-performance, cost-effective solutions.

II. Core Product Features and Clinical Value

The "Radiofrequency Coagulation Electrode Cannula Needle" promoted by Beiqi Medical (model number such as 240102) features the following outstanding characteristics:

• Precision needle tip and "zero-thickness transition" design: The needle tip undergoes special processing to achieve exceptional sharpness, significantly reducing patient discomfort during puncture. The core technology lies in the "zero-thickness transition" between the insulating layer (typically polytetrafluoroethylene, or Teflon) and the exposed metal shaft end. This smooth transition eliminates any step-like sensation that may occur with conventional coatings, providing clinicians with an exceptionally smooth puncture feel, enabling more precise and controllable procedures-particularly critical when targeting delicate areas such as nerve roots and facet joints.
• Reliable insulation performance: Except for the exposed active portion at the tip, the entire needle shaft is coated with a robust insulating layer. This ensures that radiofrequency current is delivered exclusively from the tip, precisely targeting the intended nerve without causing unnecessary thermal damage to surrounding healthy tissues along the puncture path. Products distributed by Beiqi utilize heat-shrunk Teflon technology, resulting in a much thicker coating than traditional electrostatic spraying methods, thereby offering superior insulation and enhanced safety.
• Comprehensive specifications and broad compatibility: The product line offers a wide range of sizes, including diameters from 0.7mm to 0.9mm (corresponding to 20G–22G), lengths from 50mm to 120mm, and exposed tip lengths from 4mm to 10mm. This extensive selection allows physicians to choose the most suitable needle based on the depth and size of the target nerves (such as trigeminal nerves, posterior spinal nerves, lumbar intervertebral discs, etc.), enabling personalized treatment approaches.
• Full compatibility: This cannula needle not only pairs seamlessly with Beiqi's own radiofrequency coagulator to achieve precise closed-loop temperature control but is also compatible with other leading RF generators, offering clinicians flexible options in clinical practice.

III. Domestication Process and Independent Innovation

Although imported products have met high-end clinical demands, Beiqi Medical has not ceased its pursuit of independent innovation. Since its establishment, the company has achieved several firsts in China's pain radiofrequency equipment field: for instance, it launched the country's first 0.4mm-diameter pain radiofrequency electrode and the first 0.7mm-diameter radiofrequency cannula needle in 2007; that same year, it also introduced China's first radiofrequency coagulator equipped with pulse radiofrequency and dual stimulation modes (voltage/current). These innovations have significantly enriched the range of interventional pain treatment options available domestically.

Beiqi Medical's pain radiofrequency product line has obtained certifications from multiple countries, including the EU CE, Malaysia MDA, and Australia TGA, and has also achieved ISO13485 certification for medical device quality management systems, enabling "Made in China" minimally invasive pain treatment devices to reach the global market. Its independently developed series of radiofrequency temperature-controlled coagulators, renowned for their excellent cost-performance ratio, have established stable and solid cooperative relationships with domestic clinical pain therapy experts.

IV. Clinical Applications and Market Outlook

The radiofrequency coagulation electrode cannula needle is primarily used for minimally invasive treatment of various chronic, refractory pain conditions, including postherpetic neuralgia, trigeminal neuralgia, cervical and lumbar discogenic pain, and facet joint syndrome. When connected to a radiofrequency generator, it delivers controllable RF thermal energy through the needle tip, selectively ablating pain-sensing nerve fibers to achieve long-term pain relief.

As the population ages and people's expectations for quality of life rise, the market for chronic pain treatment continues to grow. Beiqi Medical has adopted a dual-drive model combining "distribution of high-end imported consumables with independent development of core equipment," ensuring benchmark clinical efficacy while reducing treatment accessibility through domestically produced devices. In the future, as domestic material technologies advance and clinical data accumulate, fully homegrown high-performance radiofrequency puncture needles are expected to gradually replace imported alternatives, enabling a broader patient population to benefit from safe, effective, and accessible minimally invasive interventional treatments.